GGrantIndex
← Leaderboards

Abhijit Patel

Yale University

$5,506,607
Attributed
$7,691,933
Total exposure
4
Grants
2
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2M · FY201625
$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$10,253,910 · 5

By mechanism

U01$3,390,181 · 1
U2C$2,561,977 · 1
R44$1,999,999 · 1
R01$1,903,713 · 1
R43$398,040 · 1

Top collaborators

Most similar at Yale University

Same institution · by research overlap

Others in their field

Top investigators on “Performance

Research focus

PerformanceBloodMutationDetectionMalignant NeoplasmsTumor DnaMutantSpecificityCancer BiomarkersBlood TestsSomatic MutationBiological MarkersMalignant Neoplasm Of LungTumorCancer TypeSuccessSamplingBlood CirculationSensitivity And SpecificityBaseTumor-DerivedMorphologic ArtifactsNext Generation SequencingX-Ray Computed Tomography

Grant awards (16)

Monitoring Immunotherapy Response via Gene Silencing Landscapes in Cell-Free DNA$1,009,228
R44 · FY2025 · CA
Genome-wide methylation and proteomic analysis of uterine lavage and cervical swab for early detection of ovarian cancer$952,713
U2C · FY2025 · CA
Monitoring Immunotherapy Response via Gene Silencing Landscapes in Cell-Free DNA$990,771
R44 · FY2024 · CA
Genome-wide methylation and proteomic analysis of uterine lavage and cervical swab for early detection of ovarian cancer$922,892
U2C · FY2023 · CA
Monitoring Immunotherapy Response via Gene Silencing Landscapes in Cell-Free DNA$398,040
R43 · FY2023 · CA
Lung Cancer Screening via Ultrasensitive and Cost-efficient Analysis of Tumor DNA Signatures in Blood$947,748
U01 · FY2022 · CA · contact PI
Genome-wide methylation and proteomic analysis of uterine lavage and cervical swab for early detection of ovarian cancer$686,372
U2C · FY2022 · CA
Lung Cancer Screening via Ultrasensitive and Cost-efficient Analysis of Tumor DNA Signatures in Blood$967,088
U01 · FY2021 · CA · contact PI
Lung Cancer Screening via Ultrasensitive and Cost-efficient Analysis of Tumor DNA Signatures in Blood$450,480
U01 · FY2020 · CA · contact PI
Circulating DNA as a Marker of Treatment Efficacy and Failure in Lung Cancer$383,156
R01 · FY2020 · CA · contact PI
Lung Cancer Screening via Ultrasensitive and Cost-efficient Analysis of Tumor DNA Signatures in Blood$504,629
U01 · FY2019 · CA · contact PI
Circulating DNA as a Marker of Treatment Efficacy and Failure in Lung Cancer$371,660
R01 · FY2019 · CA · contact PI
Lung Cancer Screening via Ultrasensitive and Cost-efficient Analysis of Tumor DNA Signatures in Blood$520,236
U01 · FY2018 · CA · contact PI
Circulating DNA as a Marker of Treatment Efficacy and Failure in Lung Cancer$383,156
R01 · FY2018 · CA · contact PI
Circulating DNA as a Marker of Treatment Efficacy and Failure in Lung Cancer$383,156
R01 · FY2017 · CA · contact PI
Circulating DNA as a Marker of Treatment Efficacy and Failure in Lung Cancer$382,585
R01 · FY2016 · CA · contact PI